Lun - Ven 8:00 - 17:00

Biodiversité

Parce que chaque espèce joue un rôle particulier dans l’écosystème, elle est précieuse

Education environnementale
Education environnementale

L'éducation environnementale sensibilise, surtout les jeunes, à nos ressources et à leur usage durable.

Ecotourisme
Ecotourisme

L'écotourisme préserve la nature, implique les communautés locales et offre des expériences durables.

Développement Communautaire
Développement Communautaire

Moins dépendance forestière, plus de sécurité alimentaire, préservation des ressources.

ODDB ONG

Label: TADALAFIL tablet

Tadalafil > tadalafil 40mg


Hypersensitivity reactions have been reported, including Stevens-Johnson syndrome and exfoliative dermatitis [see Adverse Reactions (6.2)]. Tadalafil tablet is contraindicated in patients who are using any form of organic nitrate, either regularly or intermittently. This potentiation is thought to result from the combined effects of nitrates and tadalafil tablets on the nitric oxide/cGMP pathway [see Clinical Pharmacology (12.2)].

  • Do not take Tadalafil 40mg if you are on medications containing nitrates.
  • Follow the prescribed dosing schedule strictly for safety and effectiveness.
  • The medication may cause a sudden drop in blood pressure in some users.
  • Inform your doctor about all health conditions before starting Tadalafil.
  • Do not take more than one dose per day to avoid overdose risks.
  • Use this medication responsibly to manage ED effectively and safely.

Coadministration of GC stimulator such as riociguat with tadalafil tablets is contraindicated. Tadalafil tablets may potentiate the hypotensive effects of GC stimulators. Tadalafil tablets are contraindicated in patients with a known serious hypersensitivity to tadalafil (tadalafil tablets or CIALIS). 5 WARNINGS AND PRECAUTIONS 5.1 HypotensionTadalafil tablets has vasodilatory properties that may result in transient decreases in blood pressure. Prior to prescribing tadalafil tablets, carefully consider whether patients with underlying cardiovascular disease could be affected adversely by such vasodilatory effects. Patients with preexisting hypotension, with autonomic dysfunction, with left ventricular outflow obstruction, may be particularly sensitive to the actions of vasodilators.5.2 Worsening Pulmonary Vascular Occlusive DiseasePulmonary vasodilators may significantly worsen the cardiovascular status of patients with pulmonary veno-occlusive disease (PVOD). Since there are no clinical data on administration of tadalafil tablets to patients with veno-occlusive disease, administration of tadalafil tablets to such patients is not recommended. Should signs of pulmonary edema occur when tadalafil tablets are administered, the possibility of associated PVOD should be considered.5.3 Visual LossWhen used to treat erectile dysfunction, non–arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision, including permanent loss of vision, has been reported postmarketing in temporal association with the use of phosphodiesterase type 5 (PDE-5) inhibitors, including tadalafil. Most, but not all, of these patients had underlying anatomic or vascular risk factors for development of NAION, including but not necessarily limited to: low cup to disc ratio (“crowded disc”), age over 50, diabetes, hypertension, coronary artery disease, hyperlipidemia, and smoking.

Should you take tadalafil daily? 7 questions to ask yourself before you decide

Hypersensitivity reactions have been reported, including Stevens-Johnson syndrome and exfoliative dermatitis [see Adverse Reactions (6.2)]. Tadalafil tablet is contraindicated in patients who are using any form of organic nitrate, either regularly or intermittently. This potentiation is thought to result from the combined effects of nitrates and tadalafil tablets on the nitric oxide/cGMP pathway [see Clinical Pharmacology (12.2)]. Coadministration of GC stimulator such as riociguat with tadalafil tablets is contraindicated. Tadalafil tablets may potentiate the hypotensive effects of GC stimulators.

What is the benefit of tadalafil?

Tadalafil tablets are contraindicated in patients with a known serious hypersensitivity to tadalafil (tadalafil tablets or CIALIS). 5 WARNINGS AND PRECAUTIONS 5.1 HypotensionTadalafil tablets has vasodilatory properties that may result in transient decreases in blood pressure. Prior to prescribing tadalafil tablets, carefully consider whether patients with underlying cardiovascular disease could be affected adversely by such vasodilatory effects. Patients with preexisting hypotension, with autonomic dysfunction, with left ventricular outflow obstruction, may be particularly sensitive to the actions of vasodilators.5.2 Worsening Pulmonary Vascular Occlusive DiseasePulmonary vasodilators may significantly worsen the cardiovascular status of patients with pulmonary veno-occlusive disease (PVOD). Since there are no clinical data on administration of tadalafil tablets to patients with veno-occlusive disease, administration of tadalafil tablets to such patients is not recommended.

Tadalafil for Chronic Obstructive Pulmonary Disease (COPD)

Should signs of pulmonary edema occur when tadalafil tablets are administered, the possibility of associated PVOD should be considered.5.3 Visual LossWhen used to treat erectile dysfunction, non–arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision, including permanent loss of vision, has been reported postmarketing in temporal association with the use of phosphodiesterase type 5 (PDE-5) inhibitors, including tadalafil. Most, but not all, of these patients had underlying anatomic or vascular risk factors for development of NAION, including but not necessarily limited to: low cup to disc ratio (“crowded disc”), age over 50, diabetes, hypertension, coronary artery disease, hyperlipidemia, and smoking. Based on published literature, the annual incidence of NAION is 2.5-11.8 cases per 100,000 in males aged greater than or equal to 50 in the general population. An observational case-crossover study evaluated the risk of NAION when PDE5 inhibitor use, as a class, typical of erectile dysfunction treatment, occurred immediately before NAION onset (within 5 half-lives), compared to PDE5 inhibitor use in a prior time period. The results suggest an approximate 2-fold increase in the risk of NAION, with a risk estimate of 2.15 (95% CI 1.06, 4.34). Based on published literature, the annual incidence of NAION is 2.5-11.8 cases per 100,000 in males aged greater than or equal to 50 in the general population. An observational case-crossover study evaluated the risk of NAION when PDE5 inhibitor use, as a class, typical of erectile dysfunction treatment, occurred immediately before NAION onset (within 5 half-lives), compared to PDE5 inhibitor use in a prior time period. The results suggest an approximate 2-fold increase in the risk of NAION, with a risk estimate of 2.15 (95% CI 1.06, 4.34). A similar study reported a consistent result, with a risk estimate of 2.27 (95% CI 0.99, 5.20).

  • Tadalafil 40mg has a longer duration of action compared to some ED drugs.
  • The medication can be taken with or without food, based on personal preference.
  • Seek immediate medical help if you experience an erection lasting over 4 hours.
  • Tadalafil 40mg might interact with certain antifungal or antibiotic drugs.
  • Dose adjustments are necessary for patients with certain health conditions.
  • Always check for drug interactions before starting Tadalafil 40mg.

Other risk factors for NAION, such as the presence of “crowded” optic disc, may have contributed to the occurrence of NAION in these studies.Patients with known hereditary degenerative retinal disorders, including retinitis pigmentosa, were not included in the clinical trials, and use in these patients is not recommended.5.4 Hearing ImpairmentCases of sudden decrease or loss of hearing, which may be accompanied by tinnitus and dizziness, have been reported in patients taking tadalafil.

Product Dosage Quantity + Bonus Price
Cialis Generic2.5mg60 + 4 Pills83.43€ 79.46€
Cialis Generic40mg20 Pills59.47€ 56.64€
Cialis Generic20mg10 Pills31.49€ 29.99€
Cialis Generic10mg10 Pills31.41€ 29.91€
Cialis Generic10mg60 + 6 Pills105.81€ 100.77€
Cialis Generic10mg120 + 6 Pills178.49€ 169.99€
Cialis Generic5mg180 + 10 Pills159.65€ 152.05€
Cialis Generic60mg60 + 4 Pills145.06€ 138.15€
Tadalista Super Active20mg120 + 16 Pills382.15€ 363.95€
Cialis Generic20mg60 + 6 Pills117.76€ 112.15€
Cialis Generic2.5mg270 + 10 Pills199.64€ 190.13€
Cialis Generic5mg360 + 10 Pills268.08€ 255.31€

It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or to other factors [see Adverse Reactions (6.2)].5.5 Combination with Other PDE5 InhibitorsTadalafil is also marketed for erectile dysfunction. The safety and efficacy of taking tadalafil tablets together with another PDE5 inhibitor has not been studied.

  • Tadalafil 40mg is a higher dose used for severe erectile dysfunction.
  • Always consult a doctor before taking Tadalafil 40mg.
  • Avoid alcohol when using Tadalafil 40mg to prevent side effects.
  • Tadalafil 40mg should not be used more than once in 24 hours.
  • Possible side effects include headache, flushing, and nasal congestion.
  • Do not take Tadalafil 40mg with nitrates or alpha-blockers.

Inform patients taking tadalafil tablets not to take other PDE5 inhibitors.5.6 Prolonged ErectionThere have been reports of prolonged erections greater than 4 hours and priapism (painful erections greater than 6 hours in duration) for this class of compounds.

5.4 Hearing Impairment

Others were reported to have occurred hours to days after the use of tadalafil and sexual activity. It is not possible to determine whether these events are related directly to tadalafil, to sexual activity, to the patient’s underlying cardiovascular disease, to a combination of these factors, or to other factors.Body as a whole — Hypersensitivity reactions including urticaria, Stevens–Johnson syndrome, and exfoliative dermatitisNervous — Migraine, seizure and seizure recurrence, and transient global amnesiaOphthalmologic — Visual field defect, retinal vein occlusion, retinal artery occlusion, and NAION [see Warnings and Precautions (5.3) and Patient Counseling Information (17)].Otologic — Cases of sudden decrease or loss of hearing have been reported postmarketing in temporal association with the use of PDE5 inhibitors, including tadalafil. In some of the cases, medical conditions and other factors were reported that may have also played a role in the otologic adverse events. In many cases, medical follow-up information was limited. Patients with conditions that might predispose them to priapism (such as sickle cell anemia, multiple myeloma, or leukemia), or in patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie’s disease) are at an increased risk.

Contraindication Explanation Alternative Actions
Nitrates use Can cause severe hypotension Consult doctor for alternatives
Severe liver impairment Reduced drug clearance Adjust dose or avoid
Recent stroke or heart attack Risk of adverse cardiovascular events Monitor closely
Hypotension Blood pressure too low Treat underlying causes

Priapism, if not treated promptly, can result in irreversible damage to the erectile tissue. Patients who have an erection lasting greater than 4 hours, whether painful or not, should seek emergency medical attention. Tadalafil tablets has vasodilatory properties that may result in transient decreases in blood pressure. Patients with preexisting hypotension, with autonomic dysfunction, with left ventricular outflow obstruction, may be particularly sensitive to the actions of vasodilators. Pulmonary vasodilators may significantly worsen the cardiovascular status of patients with pulmonary veno-occlusive disease (PVOD). Should signs of pulmonary edema occur when tadalafil tablets are administered, the possibility of associated PVOD should be considered. When used to treat erectile dysfunction, non–arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision, including permanent loss of vision, has been reported postmarketing in temporal association with the use tadalafil sale of phosphodiesterase type 5 (PDE-5) inhibitors, including tadalafil. Other risk factors for NAION, such as the presence of “crowded” optic disc, may have contributed to the occurrence of NAION in these studies. Patients with known hereditary degenerative retinal disorders, including retinitis pigmentosa, were not included in the clinical trials, and use in these patients is not recommended. Cases of sudden decrease or loss of hearing, which may be accompanied by tinnitus and dizziness, have been reported in patients taking tadalafil. It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or to other factors [see Adverse Reactions (6.2)].

6.2 Postmarketing Experience

Tadalafil is also marketed for erectile dysfunction. Inform patients taking tadalafil tablets not to take other PDE5 inhibitors. There have been reports of prolonged erections greater than 4 hours and priapism (painful erections greater than 6 hours in duration) for this class of compounds.

Side Effects

Cases of sudden decrease or loss of hearing, which may be accompanied by tinnitus and dizziness, have been reported in patients taking tadalafil. It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or to other factors [see Adverse Reactions (6.2)]. Tadalafil is also marketed for erectile dysfunction. Inform patients taking tadalafil tablets not to take other PDE5 inhibitors. There have been reports of prolonged erections greater than 4 hours and priapism (painful erections greater than 6 hours in duration) for this class of compounds.

Dosing Considerations

6 ADVERSE REACTIONS The following serious adverse reactions are discussed elsewhere in the labeling:Hypotension [see Warnings and Precautions (5.1)]Visual Loss [see Warnings and Precautions (5.3) and Patient Counseling Information (17)]Hearing loss [see Warnings and Precautions (5.4)]Priapism [see Warnings and Precautions (5.6)]6.1 Clinical Trials ExperienceBecause clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.Tadalafil was administered to 398 patients with PAH during clinical trials worldwide. In trials of tadalafil tablets, a total of 311 and 251 subjects have been treated for at least 182 days and 360 days, respectively. The overall rates of discontinuation because of an adverse event (AE) in the placebo-controlled trial were 9% for tadalafil tablets 40 mg and 15% for placebo. The rates of discontinuation because of AEs, other than those related to worsening of PAH, in patients treated with tadalafil tablets 40 mg was 4% compared to 5% in placebo-treated patients.In the placebo-controlled study, the most common AEs were generally transient and mild to moderate in intensity. Table 1 presents treatment-emergent adverse events reported by greater than or equal to 9% of patients in the tadalafil tablets 40 mg group and occurring more frequently than with placebo.6.2 Postmarketing ExperienceThe following adverse reactions have been identified during post-approval use of tadalafil.

Tadalafil for Diabetes-Related Sexual Dysfunction

These events have been chosen for inclusion either because of their seriousness, reporting frequency, lack of clear alternative causation, or a combination of these factors. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or establish a causal relationship to drug exposure. The list does not include adverse events that are reported from clinical trials and that are listed elsewhere in this section.Cardiovascular and cerebrovascular — Serious cardiovascular events, including myocardial infarction, sudden cardiac death, stroke, chest pain, palpitations, and tachycardia, have been reported postmarketing in temporal association with the use of tadalafil [see Contraindications (4.1)]. Most, but not all, of these patients had preexisting cardiovascular risk factors. Many of these events were reported to occur during or shortly after sexual activity, and a few were reported to occur shortly after the use of tadalafil without sexual activity. 6 ADVERSE REACTIONS The following serious adverse reactions are discussed elsewhere in the labeling:Hypotension [see Warnings and Precautions (5.1)]Visual Loss [see Warnings and Precautions (5.3) and Patient Counseling Information (17)]Hearing loss [see Warnings and Precautions (5.4)]Priapism [see Warnings and Precautions (5.6)]6.1 Clinical Trials ExperienceBecause clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.Tadalafil was administered to 398 patients with PAH during clinical trials worldwide. In trials of tadalafil tablets, a total of 311 and 251 subjects have been treated for at least 182 days and 360 days, respectively.

Drug Label Information

A similar study reported a consistent result, with a risk estimate of 2.27 (95% CI 0.99, 5.20). Other risk factors for NAION, such as the presence of “crowded” optic disc, may have contributed to the occurrence of NAION in these studies.Patients with known hereditary degenerative retinal disorders, including retinitis pigmentosa, were not included in the clinical trials, and use in these patients is not recommended.5.4 Hearing ImpairmentCases of sudden decrease or loss of hearing, which may be accompanied by tinnitus and dizziness, have been reported in patients taking tadalafil. It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or to other factors [see Adverse Reactions (6.2)].5.5 Combination with Other PDE5 InhibitorsTadalafil is also marketed for erectile dysfunction. The safety and efficacy of taking tadalafil tablets together with another PDE5 inhibitor has not been studied. Inform patients taking tadalafil tablets not to take other PDE5 inhibitors.5.6 Prolonged ErectionThere have been reports of prolonged erections greater than 4 hours and priapism (painful erections greater than 6 hours in duration) for this class of compounds.

Other Interactions

Patients with conditions that might predispose them to priapism (such as sickle cell anemia, multiple myeloma, or leukemia), or in patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie’s disease) are at an increased risk. Priapism, if not treated promptly, can result in irreversible damage to the erectile tissue. Patients who have an erection lasting greater than 4 hours, whether painful or not, should seek emergency medical attention. Tadalafil tablets has vasodilatory properties that may result in transient decreases in blood pressure. Patients with preexisting hypotension, with autonomic dysfunction, with left ventricular outflow obstruction, may be particularly sensitive to the actions of vasodilators.

Key takeaways

Pulmonary vasodilators may significantly worsen the cardiovascular status of patients with pulmonary veno-occlusive disease (PVOD). Should signs of pulmonary edema occur when tadalafil tablets are administered, the possibility of associated PVOD should be considered. When used to treat erectile dysfunction, non–arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision, including permanent loss of vision, has been reported postmarketing in temporal association with the use tadalafil sale of phosphodiesterase type 5 (PDE-5) inhibitors, including tadalafil. Other risk factors for NAION, such as the presence of “crowded” optic disc, may have contributed to the occurrence of NAION in these studies. Patients with known hereditary degenerative retinal disorders, including retinitis pigmentosa, were not included in the clinical trials, and use in these patients is not recommended. The overall rates of discontinuation because of an adverse event (AE) in the placebo-controlled trial were 9% for tadalafil tablets 40 mg and 15% for placebo. The rates of discontinuation because of AEs, other than those related to worsening of PAH, in patients treated with tadalafil tablets 40 mg was 4% compared to 5% in placebo-treated patients.In the placebo-controlled study, the most common AEs were generally transient and mild to moderate in intensity. Table 1 presents treatment-emergent adverse events reported by greater than or equal to 9% of patients in the tadalafil tablets 40 mg group and occurring more frequently than with placebo.6.2 Postmarketing ExperienceThe following adverse reactions have been identified during post-approval use of tadalafil. These events have been chosen for inclusion either because of their seriousness, reporting frequency, lack of clear alternative causation, or a combination of these factors. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or establish a causal relationship to drug exposure. The list does not include adverse events that are reported from clinical trials and that are listed elsewhere in this section.Cardiovascular and cerebrovascular — Serious cardiovascular events, including myocardial infarction, sudden cardiac death, stroke, chest pain, palpitations, and tachycardia, have been reported postmarketing in temporal association with the use of tadalafil [see Contraindications (4.1)]. Most, but not all, of these patients had preexisting cardiovascular risk factors. Many of these events were reported to occur during or shortly after sexual activity, and a few were reported to occur shortly after the use of tadalafil without sexual activity. Others were reported to have occurred hours to days after the use of tadalafil and sexual activity. It is not possible to determine whether these events are related directly to tadalafil, to sexual activity, to the patient’s underlying cardiovascular disease, to a combination of these factors, or to other factors.Body as a whole — Hypersensitivity reactions including urticaria, Stevens–Johnson syndrome, and exfoliative dermatitisNervous — Migraine, seizure and seizure recurrence, and transient global amnesiaOphthalmologic — Visual field defect, retinal vein occlusion, retinal artery occlusion, and NAION [see Warnings and Precautions (5.3) and Patient Counseling Information (17)].Otologic — Cases of sudden decrease or loss of hearing have been reported postmarketing in temporal association with the use of PDE5 inhibitors, including tadalafil. In some of the cases, medical conditions and other factors were reported that may have also played a role in the otologic adverse events. In many cases, medical follow-up information was limited.

 Singes à ventre roux

10+

Années d'expérience

ODDB ONG

Domaines d'interventions

Les objectifs que
nous poursuivons

Dans le cadre de notre stratégie, nous menons des actions locales dans les différentes écorégions cruciales, en visant des objectifs globaux.

Nous voulons nous assurer que les espèces les plus emblématiques et les plus menacées soient préservées et puissent évoluer librement dans la nature. Nous plaidons également pour le renforcement de l'intégrité de nos forêts les plus importantes et des avantages qu'elles procurent en termes de bien-être. Nous nous battons également pour que les futurs systèmes alimentaires soient durables et conformes aux critères de santé alimentaire. Enfin, il est nécessaire d'opérer une transition mondiale vers un avenir à faible émission de carbone.

Biodiversité

Parce que chaque espèce joue un rôle particulier dans l’écosystème, elle est précieuse

En savoir plus
Education environnementale

L'éducation environnementale sensibilise, surtout les jeunes, à nos ressources et à leur usage durable.

En savoir plus
Ecotourisme

L'écotourisme préserve la nature, implique les communautés locales et offre des expériences durables.

En savoir plus
Développement Communautaire

Moins dépendance forestière, plus de sécurité alimentaire, préservation des ressources.

En savoir plus
ODDB ONG

Nos Projets

ODDB-ONG agit pour l'environnement et le mieux-être des communautés locales.

ODDB-ONG mène des actions écologiques pour soutenir les populations locales dans leurs efforts pour améliorer leur bien-être et celui de leur environnement.

Nous voulons nous assurer que les espèces les plus emblématiques et les plus menacées soient préservées et puissent évoluer librement dans la nature. Nous plaidons également pour le renforcement de l'intégrité de nos forêts les plus importantes et des avantages qu'elles procurent en termes de bien-être. Nous nous battons également pour que les futurs systèmes alimentaires soient durables et conformes aux critères de santé alimentaire. Enfin, il est nécessaire d'opérer une transition mondiale vers un avenir à faible émission de carbone.

Merci de soutenir nos projets

Votre don nous permet d’agir, merci !

ODDB ONG

Question à nous poser

Une question d'ordre général ?

La biodiversité fait référence à la variété et à la diversité de la vie sur Terre, y compris toutes les espèces d'animaux, de plantes, de micro-organismes et les écosystèmes dans lesquels ils vivent. Cela englobe la richesse génétique au sein des espèces, la diversité des espèces elles-mêmes et la variété des habitats naturels. En résumé, la biodiversité représente la variété de la vie et des écosystèmes qui rendent notre planète unique et fonctionnelle.

Pour poursuivre nos actions pour la planète et en engager de nouvelles, nous sollicitons le soutien de tous. Chaque contribution est importante. Partagez nos campagnes, faites un don, devenez bénévole pour ODDB ONG et aidez-nous à préserver la nature.

Le logo du ODDB ONG est une marque internationale déposée et soumise au droit d'auteur. Toute utilisation ou reproduction est strictement interdite sans autorisation. Si vous souhaitez utiliser le logo dans le cadre d'un partenariat, veuillez écrire à l'adresse suivante. Pour toute autre utilisation, veuillez contacter l'adresse suivante.

Pour toute demande de stage, veuillez consulter régulièrement notre page dédiée au recrutement.

Pour commencer, il est essentiel d'adopter de bonnes habitudes quotidiennes : privilégier une alimentation équilibrée avec moins de protéines animales et favorisant les circuits courts, opter pour des modes de transport durables tels que les transports en commun ou le vélo, améliorer votre efficacité énergétique et votre utilisation numérique, et réduire la production de déchets. Toutes ces pratiques sont détaillées dans la section " Agir au quotidien".

Un accusé de réception vous est envoyé par mail pour vous confirmer la réception de votre dossier de candidature.

Les conséquences de la crise écologique sont manifestes : une agriculture en déclin, des plans d'eau épuisés, un accès difficile à l'eau douce et des forêts en difficulté pour préserver la biodiversité. Notre enjeu environnemental majeur est clair : l'urgence d'agir. Cette nécessité ne concerne plus seulement les générations futures, mais également la population actuelle, qui subit déjà les perturbations profondes engendrées par la crise écologique.
singe a ventre rouge
ODDB ONG

Galerie

Nos Actions En Image

Dendroaspis jamesoni
ODDB ONG
Dendroaspis jamesoni
Benin Potto (Perodicticus potto juju)
ODDB ONG
Benin Potto (Perodicticus potto juju)
Singe tantale (Chlorocebus aethiops tantalus)
ODDB ONG
Singe tantale (Chlorocebus aethiops tantalus)
Female Sitatunga with offspring (Tragelaphus spekii)
ODDB ONG
Female Sitatunga with offspring (Tragelaphus spekii)
Cercopithecus aethiops tantalus
ODDB ONG
Cercopithecus aethiops tantalus
Coucal noir (Centropus senegalensis)
ODDB ONG
Coucal noir (Centropus senegalensis)
Cercopithecus erythrogaster
ODDB ONG
Cercopithecus erythrogaster
Female sitatunga (Tragelaphus spekii)
ODDB ONG
Female sitatunga (Tragelaphus spekii)
Gnanhouizoun community forest, Ouémé valley
ODDB ONG
Gnanhouizoun community forest, Ouémé valley
chouette
ODDB ONG
chouette
Héron cendré (Ardea cinerea)
ODDB ONG
Héron cendré (Ardea cinerea)
Apercu de l'entrée du village Gnanhouizounmè Apercu de l'entrée du village Gnanhouizounmè Saison sèche
ODDB ONG
Apercu de l'entrée du village Gnanhouizounmè Apercu de l'entrée du village Gnanhouizounmè Saison sèche
Jacana à poitrine dorée (Actophilormis africana) Gnanhouizounmè_Bonou
ODDB ONG
Jacana à poitrine dorée (Actophilormis africana) Gnanhouizounmè_Bonou
Gnanhouizounmè au couché de soleil
ODDB ONG
Gnanhouizounmè au couché de soleil
Chamaeleo necasi
ODDB ONG
Chamaeleo necasi
Aigrette
ODDB ONG
Aigrette

Nos Statistiques

ODDB en chiffres

10+

10+

Années d'expérience

79

79Ha

de superficies reboisées

14K+

14K+

personnes sensibilisées

320

320

personnes autonomisées

151

151

Stagiaires et bénévoles formés pour suivi de la biodiversité

ODDB ONG

Nos Actualités

Actualités

Nos  Partenaires

Partenaires Techniques

little green guards Chester Zoo Institut des Tortues d'Afrique Conservatoire pour la Protection des Primates National Geographic

Partenaires Financiers

Primate Society of Great Britain SUCO INTERNATIONAL BENIN UP2GREEN The Rufford Foundation IKI